Corporate Social Responsibility | Business Wire | PR NewsWire | Marketwire | Realwire | ACN/JCN newswire | 247pressrelease | PRWeb

Viriathus Research Issues an Update Report for Viralytics Limited

Posted : Tue, 03 Nov 2009 16:03:37 GMT
Author : Viriathus Research LLC
Category : Press Release
News Alerts by Email ( click here )
News | Home
NEW YORK - (Business Wire) Viriathus Research LLC, an independent research firm, issued an Update Report today for Viralytics Limited (ASX: VLA) (OTC: VRACY), a biotechnology company that is developing therapies and drugs for the treatment of cancer in Australia.

The report provides an update on Viralytics Limited’s business, industry, product, strategy, management team, and investment opportunities and risks.

The report is available free of charge at: http://www.viriathus.com/Research/VLA_AU_Viralytics_Ltd-Update_Report-November_2009.pdf

About Viriathus Research LLC

Viriathus Research is a quality-leading New York based independent equity research company that provides insightful, in-depth research coverage and informational reports to emerging growth companies worldwide and the institutions that invest in them.

For further information on Viriathus Research, please visit www.viriathus.com/Research.htm

About Viralytics Limited

Viralytics is pioneering revolutionary new cancer therapies using oncolytic viruses to seek out and destroy cancer cells. Researchers have found that certain viruses have the capacity to preferentially target, infect and destroy cancer cells without causing excessive damage to surrounding normal tissue. The Company’s lead product CAVATAK™ is a form of Coxsackievirus A21 (CVA21), a naturally occurring common cold virus in human clinical trials, this virus has demonstrated bio-activity at low doses, rapid action, and has been well tolerated by patients. The preliminary human data support indications of anti-cancer activity of CAVATAK™ previously displayed in animal models.

For further information on Viralytics Limited, please visit www.viralytics.com.

Statement under the Private Securities Litigation Reform Act

With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to the ability of the Company to increase revenues in the future due to the developing and unpredictable markets for its products, the ability to achieve a positive cash flow, the ability to obtain orders for or install its products, the ability to obtain new customers and the ability to continue to commercialize its products, which could cause actual results or revenues to differ materially from those contemplated by these statements.

Viriathus Research LLC received $5,000 from the subject company in return for report authoring and distribution services.

Viriathus Research LLC
Lisa Springer, CFA
212-372-3116
lisa.springer@viriathus.com
www.viriathus.com
or
Viralytics Limited
Bryan Dulhunty, +61 2 9499 3200
Managing Director & CEO
www.viralytics.com


Copyright © 2008 Business Wire. All rights reserved.
Share/Save/Bookmark

Article : Viriathus Research Issues an Update Report for Viralytics Limited
Print this article
Share this article

Stay Updated

News gadget on your Google homepage
Subscribe to a news feed in Google Reader



Related News

Teledata ICT of Ghana Selects VocalTec for Class-5 VoIP
HERZLIA, Israel - VocalTec Communications Ltd. (NASDAQ:VOCL) (the “Company” or “VocalTec”), a global provider of carrier-class multimedia and voice-over-IP solutions for communication service providers, today announced that Teledata ICT, a Ghana-based licensed ISP, se

Ipsen Initiates an Advanced Endometrial Cancer Program with BN83495, its First-in-Class Steroid Sulfatase (STS) Inhibitor First Patient Dosed in Phase II
PARIS - Regulatory News: Ipsen (Paris:IPN) today announced the initiation of an international, multi-center, controlled, randomized Phase II clinical trial to evaluate the safety and efficacy of BN83495, its investigational first-in-class steroid sulfa

Nortel Selects Ericsson and Kapsch as Successful Bidders for GSM/GSM-R Business
TORONTO, ONTARIO -- 11/25/09 -- Nortel(1) Networks Corporation (OTCBB: NRTLQ) announced that it, its principal operating subsidiary Nortel Networks Limited (NNL), and certain of its other subsidiaries, including Nortel Networks Inc., Nortel Network..

Incyte Announces Major Collaboration and License Agreement for Two Hematology-Oncology Programs
WILMINGTON, Del. - Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofib

New Book is a Guide to Killer Online Press Releases for PR Pros and Small Businesses
The optimized press release (or SEO press release) is revitalizing the traditional press release. Combined with social media, news can be a powerful online marketing tool. A new book tells PR professionals, entrepreneurs and small business the secrets to killer online press releases./I/P ...

gategroup Signs Multiple Contracts With Delta Air Lines
ZURICH, Nov. 25 /PRNewswire/ -- gategroup announced the completion of major contract renewals with Delta Air Lines and its Northwest Airlines subsidiary as part of the carriers' continuing progress to integrate supply contracts. The multi-year deal, encompassing more tha...

BLADE Network Technologies and Emulex Deliver Essential Networking Components for IBM BladeCenter Virtual Fabric
PARIS - Emulex Corporation (NYSE:ELX) and BLADE Network Technologies, Inc. (

Have your Say
Name
Email
Subject
Your Comment

Enter Verification code
 
  

 
Follow The Earth Times
Subscribe to RSS Follow Earth Times on TwitterNews by email
Share/Save/Bookmark
 
 



 
Subscribe to free Earthtimes
News Alerts by Email Click here
For RSS Feeds Click here
or Create your own RSS

Add to Google Toolbar
Breaking News
Press Releases

 


The Earth Times
News Category

© 2009 www.earthtimes.org, The Earth Times, All Rights Reserved | Privacy Policy
Earth Times accept no responsibility or liability either directly or indirectly for views or opinions expressed in articles or comments.